<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-106682</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Dermatofibrosarcoma Protuberans</dc:title>
<dc:description xml:lang="en">Dermatofibrosarcoma protuberans is the most common skin sarcoma, although its incidence is very low compared with other skin tumors. It presents as a slow-growing indurated plaque on which nodules develop over time. The lesion arises in the dermis but can invade subcutaneous tissue, fascia, muscle and even bone. COL1A1-PDGFB translocation is specific to dermatofibrosarcoma protuberans, and the presence of this fusion contributes to diagnosis in certain cases. A review of the literature provides evidence that recurrence is much lower after Mohs micorgraphic surgery than after conventional wide local excision. In the case of metastatic disease or when surgery would be mutilating, another recently approved treatment is the tyrosine kinase inhibitor imatinib (AU)</dc:description>
<dc:creator>Serra-Guillén, C</dc:creator>
<dc:creator>Llombart, B</dc:creator>
<dc:creator>Sanmartín, O</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El dermatofibrosarcoma protuberans es el sarcoma de piel más frecuente aunque su incidencia es muy baja comparada con otros tumores cutáneos. Se presenta clínicamente en forma de placa indurada de crecimiento lento sobre la que aparecen nódulos a medida que el tumor progresa. Se localiza inicialmente en la dermis desde donde infiltra el tejido celular subcutáneo, la fascia, el músculo e incluso el hueso. La translocación COL1A1-PDGFB es específica del dermatofibrosarcoma protuberans y sirve de ayuda en el diagnóstico de determinados casos. Según la revisión de las series publicadas en la literatura, el porcentaje de recidivas con cirugía micrográfica de Mohs es mucho menor que el encontrado cuando se emplea cirugía convencional con márgenes amplios. Para casos metastásicos o en aquellos donde la cirugía pueda ser mutilante se dispone recientemente del imatinib, fármaco de la familia de los inhibitores de la tirosina quinasa (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;103(9): 762-777, nov. 2012. ilus, tab</dc:source>
<dc:identifier>ibc-106682</dc:identifier>
<dc:title xml:lang="es">Dermatofibrosarcoma protuberans</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d22921^s22048</dc:subject>
<dc:subject>^d31514^s22009</dc:subject>
<dc:subject>^d32848</dc:subject>
<dc:subject>^d22921^s22039</dc:subject>
<dc:subject>^d22921^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3600^s22045</dc:subject>
<dc:subject>^d22921^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d31146^s22073</dc:subject>
<dc:subject>^d31514^s22032</dc:subject>
<dc:subject>^d31514^s29166</dc:subject>
<dc:subject>^d29051^s22045</dc:subject>
<dc:subject>^d29051^s22066</dc:subject>
<dc:subject>^d31514^s22012</dc:subject>
<dc:subject>^d31514^s22046</dc:subject>
<dc:subject>^d36103</dc:subject>
<dc:subject>^d31514^s22016</dc:subject>
<dc:subject>^d34467^s22001</dc:subject>
<dc:type>article</dc:type>
<dc:date>201211</dc:date>
</metadata>
</record>
</ibecs-document>
